We are analyzing https://link.springer.com/article/10.1007/s11883-020-0823-5.

Title:
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases | Current Atherosclerosis Reports
Description:
Purpose of Review Reduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemia as well as reduced high-density lipoprotein cholesterol (HDL-C) remain as residual risk factors of atherosclerotic cardiovascular diseases (ASCVD). To treat patients with hypertriglyceridemia and/or low HDL-C, drugs such as fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids have been used. However, fibrates were demonstrated to cause side effects such as liver dysfunction and increase in creatinine levels, and thus large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD. The failure could be attributed to their low selectivity and potency for binding to peroxisome proliferator-activated receptor (PPAR) α. To resolve these issues, the concept of selective PPARα modulator (SPPARMα) with a superior balance of efficacy and safety has been proposed and pemafibrate (K-877) has been developed. Recent Findings Pemafibrate, one of SPPARMsα, was synthesized by Kowa Company, Ltd. for better efficiency and safety. Clinical trials in Japan have established the superiority of pemafibrate on effects on serum triglycerides (TG) reduction and HDL-C elevation as well safety. Although available fibrates showed worsening of liver and kidney function test values, pemafibrate indicated improved liver function test values and was less likely to increase serum creatinine or decrease estimated glomerular filtration rate (eGFR). Very few drug-drug interactions were observed even when used concomitantly with statins. Furthermore, pemafibrate is metabolized in the liver and excreted into the bile, while many of available fibrates are mainly excreted from the kidney. Therefore, pemafibrate can be used safely even in patients with impaired renal function since there is no significant increase in its blood concentration. A large-scale trial of pemafibrate, PROMINENT, for dyslipidemic patients with type 2 diabetes is ongoing. Summary Pemafibrate is one of novel SPPARMsα and has superior benefit-risk balance compared to conventional fibrates and can be applicable for patients for whom the usage of existing fibrates is difficult such as those who are taking statins or patients with renal dysfunction. In the current review, all the recent data on pemafibrate will be summarized.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,182 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pemafibrate, pubmed, article, google, scholar, cas, patients, pparα, fibrates, liver, fenofibrate, levels, effects, selective, cholesterol, receptor, study, peroxisome, spparmα, lipoprotein, proliferatoractivated, diabetes, increased, atherosclerosis, modulator, clinical, reduced, central, serum, efficacy, activation, dyslipidemia, disease, mice, metabolism, expression, function, type, safety, treatment, genes, plasma, effect, events, hdlc, insulin, statins, increase, ppar, lipid,

Topics {✒️}

peroxisome proliferator-activated receptor-alpha peroxisome proliferator-activated receptor peroxisome proliferator-activated receptors diacylglycerol-protein kinase c-nad ppar-alpha selective agonist partial pro-estrogenic activity targeted gene-selective activities receptor–cofactor binding profile high-density lipoprotein cholesterol high-density lipoprotein function apo c-iii interact ldl receptor-null mice dearylated/dicarboxylic acid forms article download pdf improved benefit-risk balance acyl-coa synthetase genes hepatic acyl-coa synthase 1 mg/kg body weight 250 mg/kg body weight low-density lipoprotein synthesis long-term continuous benefit hyperinsulinemic-euglycemic clamp technique apo c-iii levels benefit-risk balance compared creatinine clearance-dependent manner estrogen receptor modulator pparalpha/gamma activator aleglitazar de la llera-moya large lipid-binding pocket open access published liver function-related parameters tg-rich ldl particles large-scale clinical trials long-term cardiovascular risk large-scale clinical study selective pparα modulator selective pparalpha modulator low-density lipoprotein strong anti-inflammatory effect apo c-iii glucose-stimulated insulin secretion fatty acid β-oxidation open acid form small dense ldl tg-hydrolyzed remnant lipoproteins transcription factors nf-kappab activated ppar binds pparα regulates lipid suppresses macrophage activation suggesting anti-inflammatory effects

Questions {❓}

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
         description:Reduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemia as well as reduced high-density lipoprotein cholesterol (HDL-C) remain as residual risk factors of atherosclerotic cardiovascular diseases (ASCVD). To treat patients with hypertriglyceridemia and/or low HDL-C, drugs such as fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids have been used. However, fibrates were demonstrated to cause side effects such as liver dysfunction and increase in creatinine levels, and thus large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD. The failure could be attributed to their low selectivity and potency for binding to peroxisome proliferator-activated receptor (PPAR) α. To resolve these issues, the concept of selective PPARα modulator (SPPARMα) with a superior balance of efficacy and safety has been proposed and pemafibrate (K-877) has been developed. Pemafibrate, one of SPPARMsα, was synthesized by Kowa Company, Ltd. for better efficiency and safety. Clinical trials in Japan have established the superiority of pemafibrate on effects on serum triglycerides (TG) reduction and HDL-C elevation as well safety. Although available fibrates showed worsening of liver and kidney function test values, pemafibrate indicated improved liver function test values and was less likely to increase serum creatinine or decrease estimated glomerular filtration rate (eGFR). Very few drug-drug interactions were observed even when used concomitantly with statins. Furthermore, pemafibrate is metabolized in the liver and excreted into the bile, while many of available fibrates are mainly excreted from the kidney. Therefore, pemafibrate can be used safely even in patients with impaired renal function since there is no significant increase in its blood concentration. A large-scale trial of pemafibrate, PROMINENT, for dyslipidemic patients with type 2 diabetes is ongoing. Pemafibrate is one of novel SPPARMsα and has superior benefit-risk balance compared to conventional fibrates and can be applicable for patients for whom the usage of existing fibrates is difficult such as those who are taking statins or patients with renal dysfunction. In the current review, all the recent data on pemafibrate will be summarized.
         datePublished:2020-01-23T00:00:00Z
         dateModified:2020-01-23T00:00:00Z
         pageStart:1
         pageEnd:17
         sameAs:https://doi.org/10.1007/s11883-020-0823-5
         keywords:
            Peroxisome proliferator-activated receptor alpha (PPARα)
            Selective PPAR alpha modulator (SPPARMα)
            Pemafibrate
            Triglycerides
            Dyslipidemia
            Angiology
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-020-0823-5/MediaObjects/11883_2020_823_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-020-0823-5/MediaObjects/11883_2020_823_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-020-0823-5/MediaObjects/11883_2020_823_Fig3_HTML.png
         isPartOf:
            name:Current Atherosclerosis Reports
            issn:
               1534-6242
               1523-3804
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Shizuya Yamashita
               affiliation:
                     name:Rinku General Medical Center
                     address:
                        name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Daisaku Masuda
               affiliation:
                     name:Rinku General Medical Center
                     address:
                        name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuji Matsuzawa
               affiliation:
                     name:Sumitomo Hospital
                     address:
                        name:Sumitomo Hospital, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
      description:Reduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemia as well as reduced high-density lipoprotein cholesterol (HDL-C) remain as residual risk factors of atherosclerotic cardiovascular diseases (ASCVD). To treat patients with hypertriglyceridemia and/or low HDL-C, drugs such as fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids have been used. However, fibrates were demonstrated to cause side effects such as liver dysfunction and increase in creatinine levels, and thus large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD. The failure could be attributed to their low selectivity and potency for binding to peroxisome proliferator-activated receptor (PPAR) α. To resolve these issues, the concept of selective PPARα modulator (SPPARMα) with a superior balance of efficacy and safety has been proposed and pemafibrate (K-877) has been developed. Pemafibrate, one of SPPARMsα, was synthesized by Kowa Company, Ltd. for better efficiency and safety. Clinical trials in Japan have established the superiority of pemafibrate on effects on serum triglycerides (TG) reduction and HDL-C elevation as well safety. Although available fibrates showed worsening of liver and kidney function test values, pemafibrate indicated improved liver function test values and was less likely to increase serum creatinine or decrease estimated glomerular filtration rate (eGFR). Very few drug-drug interactions were observed even when used concomitantly with statins. Furthermore, pemafibrate is metabolized in the liver and excreted into the bile, while many of available fibrates are mainly excreted from the kidney. Therefore, pemafibrate can be used safely even in patients with impaired renal function since there is no significant increase in its blood concentration. A large-scale trial of pemafibrate, PROMINENT, for dyslipidemic patients with type 2 diabetes is ongoing. Pemafibrate is one of novel SPPARMsα and has superior benefit-risk balance compared to conventional fibrates and can be applicable for patients for whom the usage of existing fibrates is difficult such as those who are taking statins or patients with renal dysfunction. In the current review, all the recent data on pemafibrate will be summarized.
      datePublished:2020-01-23T00:00:00Z
      dateModified:2020-01-23T00:00:00Z
      pageStart:1
      pageEnd:17
      sameAs:https://doi.org/10.1007/s11883-020-0823-5
      keywords:
         Peroxisome proliferator-activated receptor alpha (PPARα)
         Selective PPAR alpha modulator (SPPARMα)
         Pemafibrate
         Triglycerides
         Dyslipidemia
         Angiology
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-020-0823-5/MediaObjects/11883_2020_823_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-020-0823-5/MediaObjects/11883_2020_823_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-020-0823-5/MediaObjects/11883_2020_823_Fig3_HTML.png
      isPartOf:
         name:Current Atherosclerosis Reports
         issn:
            1534-6242
            1523-3804
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Shizuya Yamashita
            affiliation:
                  name:Rinku General Medical Center
                  address:
                     name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Daisaku Masuda
            affiliation:
                  name:Rinku General Medical Center
                  address:
                     name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuji Matsuzawa
            affiliation:
                  name:Sumitomo Hospital
                  address:
                     name:Sumitomo Hospital, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Current Atherosclerosis Reports
      issn:
         1534-6242
         1523-3804
      volumeNumber:22
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Rinku General Medical Center
      address:
         name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
         type:PostalAddress
      name:Rinku General Medical Center
      address:
         name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
         type:PostalAddress
      name:Sumitomo Hospital
      address:
         name:Sumitomo Hospital, Osaka, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Shizuya Yamashita
      affiliation:
            name:Rinku General Medical Center
            address:
               name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Daisaku Masuda
      affiliation:
            name:Rinku General Medical Center
            address:
               name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Yuji Matsuzawa
      affiliation:
            name:Sumitomo Hospital
            address:
               name:Sumitomo Hospital, Osaka, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
      name:Department of Cardiology, Rinku General Medical Center, Osaka, Japan
      name:Sumitomo Hospital, Osaka, Japan

External Links {🔗}(372)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

5.46s.

LINK . SPRINGER . COM {}